UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

	TAXOTERE (DOCETAXEL) ICTS LIABILITY LITIGATION	MDL NO. 2740				
rkobo	CISCIABILITY LITIOATION	SECTION "H" (5)				
THIS	DOCUMENT RELATES TO:	HON. JANE T. MILAZZO				
[Plaint [xx-xxx	tiff(s)] v. [Defendant(s)], EDLA No.					
		•				
	[EXEMPLAR] SHORT FORM COM	APLAINT (Effective as of May 13, 2020) ¹				
	Plaintiff(s) incorporate by reference the	e Second Amended Master Long Form Complaint				
and Jur	y Demand filed in the above referenced	d case on September 27, 2018 (Doc. 4407).				
Pursuai	nt to Pretrial Order No. 15, this [Origina	N/Amended] Short Form Complaint adopts				
allegation	ons and encompasses claims as set forti	h in the Second Amended Master Long Form				
Compla	int against Defendant(s).					
	Plaintiff(s) further allege as follows:					
1.	Plaintiff:					
2.	Spousal Plaintiff or other party making consortium):	loss of independent/secondary claim (i.e., loss of				
3.	Other type of Plaintiff and capacity (i.e., administrator, executor, guardian, conservator):					
4.	Current State of Residence:					

State in which Plaintiff(s) allege(s) injury:

5.

¹ This version of the Short FormComplaint supersedes all prior versions of the formpursuant to Pretrial Order No. 73A. This Court-approved version of the Short Form Complaint is available on the Court's Taxotere webpage and through MDL Centrality.

Defen	dants (c	heck all	Defen	dants against whom a Complaint is made):	
	a.	Taxotere Brand Name Defendants			
			A.	Sanofi US Services Inc. f/k/a Sanofi-Aventis U.S. Inc.	
			B.	Sanofi-Aventis U.S. LLC	
	b.	Other	Brand N	Name Drug Sponsors, Manufacturers, Distributors	
			A.	Sandoz Inc.	
			B.	Accord Healthcare, Inc.	
			C.	McKesson Corporation d/b/a McKesson Packaging	
			D.	Hospira Worldwide, LLC f/k/a Hospira Worldwide, Inc.	
			E.	Hospira, Inc.	
			F.	Sun Pharma Global FZE	
			G.	Sun Pharmaceutical Industries, Inc. f/k/a Caraco Pharmaceutical Laboratories Ltd.	
			H.	Pfizer Inc.	
			I.	Actavis LLC f/k/a Actavis Inc.	
			J.	Actavis Pharma, Inc.	
			K.	Sagent Pharmaceuticals, Inc.	
			L.	Other:	
Basis for Jurisdiction:					
☐ Diversity of Citizenship					
				basis for jurisdiction must be pled in sufficient detail as able Federal Rules of Civil Procedure):	

Brand Product(s) used by Plaintiff (check applicable):						
	A.	Taxotere				
	B.	Docefrez				
	C.	Docetaxel Injection				
	D.	Docetaxel Injection Concentrate				
	E.	Unknown				
	F.	Other:				
		d last date of use (or approximate date range, if specific dates are unknown identified in question 9:				
State	in which	ch Product(s) identified in question 9 was/were administered:				

12.	Nature and extent of alleged injury (including duration, approximate date of onset (if							
	known), and description of alleged injury):							
13.	Count	Counts in Master Complaint brought by Plaintiff(s):						
		Count I – Strict Products Liability – Failure to Warn						
		Count III – Negligence Count IV – Negligent Misrepresentation						
		Count V – Fraudulent Misrepresentation Count VI – Fraudulent Concealment						
		Count VII – Fraud and Deceit						
		Other: Plaintiff(s) may assert the additional theories and/or State Causes of Action against Defendant(s) identified by selecting "Other" and setting forth such claims below. If Plaintiff(s) include additional theories of recovery, for example, applicable state law or state consumer protection claims, the specific facts and allegations supporting additional theories must be pleaded by Plaintiff in sufficient detail as required by the applicable Federal Rules of Civil Procedure.						
14.	Name	of Attorney(s), Bar Number(s), Law Firm(s), Phone Number(s), Email Address(es)						
	and M	failing Address(es) representing Plaintiff(s):						
		Ву						